Difference between revisions of "Ovarian cancer laboratory findings"

Jump to: navigation, search
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{Ovarian cancer}}
{{Ovarian cancer}}
{{CMG}}; {{AE}} {{Hudakarman}}
==Laboratory finding==
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How to Edit a Page|here]]  to learn about editing.

Revision as of 20:08, 12 July 2019

Ovarian cancer Microchapters


Patient Information


Historical Perspective



Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors


Natural History, Complications & Prognosis


History & Symptoms

Physical Examination


Laboratory Findings

Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Ovarian cancer laboratory findings

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer laboratory findings

CDC on Ovarian cancer laboratory findings

Ovarian cancer laboratory findings in the news

Blogs on Ovarian cancer laboratory findings

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.


Laboratory finding

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

  • Patients with ovarian cancer can present acutely or sub-acutely
  • If there is clinical suspicion of malignancy, the evaluation includes laboratory work, imaging and surgical exploration for the definite diagnosis
  • Routine lab work
    • CBC
    • CBP
  • Serum biomarkers of epithelial ovarian cancer (EOC):
    • CA 125
      • Considered the best for ovarian cancer detection, therapeutic monitoring, and detection of the tumor recurrence
      • Postmenopausal woman: should be measured
      • Premenopausal woman: should be measured only if US shows highly suspicious malignant mass
    • HE4
      • CA125 and HE4 are used together to increase the sensitivity and specificity of ovarian cancer detection
      • Risk of Ovarian Malignancy Algorithm (ROMA) is used to decide if the patient has a high risk or low-risk malignant disease based on:
        • CA125 and HE4 levels
        • Menopausal status of the woman
    • OVA1
  • Serum biomarkers of the germ cell and sex cord-stromal ovarian cancer:
    • AFP: alpha-fetoprotein
    • hCG: human chorionic gonadotropin
    • LDH: lactate dehydrogenase
    • E2: estradiol
    • Inhibin
    • Testost: testosterone
    • Andro: androstenedione
    • DHEA: dehydroepiandrostenedione
    • AMH: anti-Müllerian hormone